The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches based on a profound understanding of its pathogenesis to halt disease progression to advanced fibrosis or cirrhosis and cancer. The pathogenesis of NAFLD involves a complex interaction among environmental factors (i.e., Western diet), obesity, changes in microbiota, and predisposing genetic variants resulting in a disturbed lipid homeostasis and an excessive accumulation of triglycerides and other lipid species in hepatocytes. Insulin resistance is a central mechanism that leads to lipotoxicity, endoplasmic reticulum stress, disturbed autophagy, and, ultimately, hepatocyte injury and death that triggers hepatic inflammation, hepatic stellate cell activation, and progressive fibrogenesis, thus driving disease progression. In the present review, we summarize the currently available data on the pathogenesis of NAFLD, emphasizing the most recent advances. A better understanding of NAFLD/NASH pathogenesis is crucial for the design of new and efficient therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BAs have emerged as important pathogenetic factors and therapeutic targets in both cholestatic and metabolic liver diseases.4 13 41”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 12,401
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,859
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Research works printed but not linked: 6
- Arab JP, 2016, Ann. Hepatol., 15, 721
- Berlanga A, 2014, Clin. Exp. Gastroenterol., 7, 221
- 10.1002/cphy.c120035 · DOI · Paper page
- Mao J-W, 2015, Int. J. Clin. Exp. Pathol., 8, 3648
- de Mesquita FC, 2015, Hepatology, 62, 901A
- Loomba R, 2016, Hepatology, 64, 1119A
Cited by
Sorted by citations
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Wang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Self-citationNovel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Self-citationShi, Y., Su, W., Zhang, L., Shi, C., Zhou, J., Wang, P., Wang, H., Shi, X., Wei, S., Wang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609060 · Cited by 177
Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071629 · Cited by 152
IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease
Park, J., Zhao, Y., Zhang, F., Zhang, S., Kwong, A. C., Zhang, Y., Hoffmann, H.-H., Bushweller, L., Wu, X., Ashbrook, A. W., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.022 · Cited by 138
Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M., & Arab, J. P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00448 · Cited by 136
Self-citationFernández, T., Viñuela, M., Vidal, C., & Barrera, F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263931 · Cited by 117
Song, K., Kwon, H., Han, C., Chen, W., Zhang, J., Ma, W., Dash, S., Gandhi, C. R., & Wu, T. (2020) · Hepatology · doi:10.1002/hep.30990 · Cited by 110
Fang, Y., Ji, L., Zhu, C., Xiao, Y., Zhang, J., Lu, J., Yin, J., & Wei, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602574 · Cited by 108
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
Fang, Z., Ruan, B., Liu, J., Duan, J., Yue, Z., Song, P., Xu, H., Ding, J., Xu, C., Dou, G., et al. (2022) · Hepatology · doi:10.1002/hep.32332 · Cited by 91
Targeting cell-intrinsic metabolism for antifibrotic therapy
Gilgenkrantz, H., Mallat, A., Moreau, R., & Lotersztajn, S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.012 · Cited by 76
Hernández, A., Reyes, D., Geng, Y., Arab, J. P., Cabrera, D., Sepulveda, R., Solis, N., Buist-Homan, M., Arrese, M., & Moshage, H. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165857 · Cited by 42
Self-citationPharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
Jin, H., Zhong, X., Zhang, C., Wu, Y., Sun, J., Wang, X., Wang, Z., Zhu, J., Jiang, Y., Du, X., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102131 · Cited by 2
Metadata
- Authors
- Arab, J. P., Arrese, M., & Trauner, M.
- Affiliations
- Mayo Clinic (US)
- Pontificia Universidad Católica de Chile (CL)
- Medical University of Vienna (AT)
- Corresponding author
- Trauner, Michael
- Venue
- Annual Review of Pathology Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2018-01-24
- Volume
- 13
- Issue
- 1
- Pages
- 321-350
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2785779482
- Cited by
- 573
- References
- 218
- Citations by year
- 2026: 43 · 2025: 64 · 2024: 76 · 2023: 85 · 2022: 61 · 2021: 93 · 2020: 77 · 2019: 47 · 2018: 26
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for the Study of Liver Diseases
- Vienna Science and Technology Fund
- Austrian Science Fund (F3008‐B19, F3517-B20, F3008, F3517)
- Fondo Nacional de Ciencia y Tecnología
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, pathogenesis, insulin resistance, lipotoxicity, endoplasmic reticulum stress, autophagy, liver inflammation, hepatic stellate cell activation, liver fibrosis, liver cirrhosis, hepatic lipid accumulation, gut microbiota, obesity, Western diet, genetic variants, cardiometabolic risk
- MeSH terms
- Animals, Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
